Buyer Name: NHS England
Buyer Address: 7&8 Wellington Place, Leeds, UKE, LS1 4AP, United Kingdom
Contact Name: Anna Salt
Contact Email: anna.salt@nhs.net
NHS Genomic Medicine Service - Most Suitable Provider Process
Buyer Contact Info
Status
complete
complete
Procedure
limited
limited
Value
5175000000.0 GBP
5175000000.0 GBP
Published
23 Oct 2025, 16:00
23 Oct 2025, 16:00
Deadline
n/a
n/a
Contract Start
n/a
n/a
Contract End
n/a
n/a
Category
services
services
CPV
85100000 - Health services
85100000 - Health services
Region
n/a
n/a
Awarded To
Manchester University NHS Foundation Trust, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Birmingham Women’s and Children’s NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, North Bristol NHS Trust, Great Ormond Street Hospital for Children NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust
Manchester University NHS Foundation Trust, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Birmingham Women’s and Children’s NHS Foundation Trust, Cambridge University Hospitals NHS Foundation Trust, North Bristol NHS Trust, Great Ormond Street Hospital for Children NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust
Official Source
Open Find a Tender
Open Find a Tender
Description
This is a notice of intention to make an award in respect of the NHS Genomic Medicine Service pursuant to the Most Suitable Provider (MSP) Process for the NHS Genomic Medicine Service (NHS GMS). For the avoidance of doubt, this is an intention to award notice. A notice of the confirmation of the award of each contract will be issued once they are signed.<br/><br/>Pursuant to the NHS GMS contracts, provider are to provide the following functions: <br/>• Organisational leadership, governance and partnership arrangements;<br/>• Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>• Laboratory operating model;<br/>• Clinical function: cancer genomics;<br/>• Clinical function: rare disease;<br/>• Clinical function: population health;<br/>• Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>• Transformation and Service Improvement;<br/>• People – workforce, education and training; and<br/>• Data and digital
Linked Documents
No linked documents found for this notice.
Opportunity Context
Lots
Lot Title: Lot 1 – NHS North-West GMS
Lot Description: Pursuant to the NHS GMS contracts, providers are to provide the following functions:<br/>* Organisational leadership, governance and partnership arrangements;<br/>* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);<br/>* Laboratory operating model;<br/>* Clinical function: cancer genomics;<br/>* Clinical function: rare disease;<br/>* Clinical function: population health;<br/>* Promotion of and supporting and leading where relevant science, research and / or innovation;<br/>* Transformation and Service Improvement;<br/>* People – workforce, education and training; and<br/>* Data and digital<br/>The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.<br/>The approximate lifetime value of the contract for all Lots is £5,175,000,000.<br/>The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).<br/>Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Lot 1 Status: cancelled
Lot 1 Has Options: Yes
Lot 1 Options: Options to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period.
Lot 1 Award Criterion (cost): Most suitable provider process with regard to the key Criteria
Lot Title: Lot 2 – NHS North-East and Yorkshire GMS
Lot 2 Status: cancelled
Lot 2 Has Options: Yes
Lot 2 Options: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period
Lot 2 Award Criterion (cost): Most suitable provider process with regard to the key Criteria
Lot Title: Lot 3 – NHS Central and South GMS
Lot 3 Status: cancelled
Lot 3 Has Options: Yes
Lot 3 Options: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period
Lot 3 Award Criterion (cost): Most suitable provider process with regard to the key Criteria
Lot Title: Lot 4 – NHS East GMS
Lot 4 Status: cancelled
Lot 4 Has Options: Yes
Lot 4 Options: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period
Lot 4 Award Criterion (cost): Most suitable provider process with regard to the key Criteria
Lot Title: Lot 5 – NHS South-West GMS
Lot 5 Status: cancelled
Lot 5 Has Options: Yes
Lot 5 Options: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period
Lot 5 Award Criterion (cost): Most suitable provider process with regard to the key Criteria
Lot Title: Lot 6 – NHS North Thames GMS
Lot 6 Status: cancelled
Lot 6 Has Options: Yes
Lot 6 Options: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period
Lot 6 Award Criterion (cost): Most suitable provider process with regard to the key Criteria
Lot Title: Lot 7 – NHS South-East GMS
Lot 7 Status: cancelled
Lot 7 Has Options: Yes
Lot 7 Options: Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period
Lot 7 Award Criterion (cost): Most suitable provider process with regard to the key Criteria
Contracts
Contract Title: Lot 1 - NHS North-West GMS
Contract Title: Lot 2 - NHS North-East and Yorkshire GMS
Contract Title: Lot 3 NHS Central and South GMS
Contract Title: Lot 4 NHS East GMS
Contract Title: Lot 5 NHS South-West GMS
Contract Title: Lot 6 NHS North Thames GMS
Contract Title: Lot 7 NHS South-East GMS
Awards
Award Title: Lot 1 - NHS North-West GMS
Award Title: Lot 2 - NHS North-East and Yorkshire GMS
Award Title: Lot 3 NHS Central and South GMS
Award Title: Lot 4 NHS East GMS
Award Title: Lot 5 NHS South-West GMS
Award Title: Lot 6 NHS North Thames GMS
Award Title: Lot 7 NHS South-East GMS
Raw Notice JSON
Expand raw payload
{
"awards": [
{
"id": "067976-2025-1",
"relatedLots": [
"1"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-18796",
"name": "Manchester University NHS Foundation Trust"
}
],
"title": "Lot 1 - NHS North-West GMS"
},
{
"id": "067976-2025-2",
"relatedLots": [
"2"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-78899",
"name": "The Newcastle upon Tyne Hospitals NHS Foundation Trust"
}
],
"title": "Lot 2 - NHS North-East and Yorkshire GMS"
},
{
"id": "067976-2025-3",
"relatedLots": [
"3"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-1009",
"name": "Birmingham Women\u2019s and Children\u2019s NHS Foundation Trust"
}
],
"title": "Lot 3 NHS Central and South GMS"
},
{
"id": "067976-2025-4",
"relatedLots": [
"4"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-6625",
"name": "Cambridge University Hospitals NHS Foundation Trust"
}
],
"title": "Lot 4 NHS East GMS"
},
{
"id": "067976-2025-5",
"relatedLots": [
"5"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-12898",
"name": "North Bristol NHS Trust"
}
],
"title": "Lot 5 NHS South-West GMS"
},
{
"id": "067976-2025-6",
"relatedLots": [
"6"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-95413",
"name": "Great Ormond Street Hospital for Children NHS Foundation Trust"
}
],
"title": "Lot 6 NHS North Thames GMS"
},
{
"id": "067976-2025-7",
"relatedLots": [
"7"
],
"status": "active",
"suppliers": [
{
"id": "GB-FTS-21063",
"name": "Guy\u0027s and St Thomas\u0027 NHS Foundation Trust"
}
],
"title": "Lot 7 NHS South-East GMS"
}
],
"bids": {
"statistics": [
{
"id": "1",
"measure": "bids",
"relatedLot": "1",
"value": 3
},
{
"id": "2",
"measure": "bids",
"relatedLot": "2",
"value": 3
},
{
"id": "3",
"measure": "bids",
"relatedLot": "3",
"value": 3
},
{
"id": "4",
"measure": "bids",
"relatedLot": "4",
"value": 3
},
{
"id": "5",
"measure": "bids",
"relatedLot": "5",
"value": 3
},
{
"id": "6",
"measure": "bids",
"relatedLot": "6",
"value": 3
},
{
"id": "7",
"measure": "bids",
"relatedLot": "7",
"value": 3
}
]
},
"buyer": {
"id": "GB-FTS-118033",
"name": "NHS England"
},
"contracts": [
{
"awardID": "067976-2025-1",
"dateSigned": "2025-10-21T00:00:00+01:00",
"id": "067976-2025-1",
"status": "active",
"title": "Lot 1 - NHS North-West GMS",
"value": {
"amount": 5175000000.0,
"currency": "GBP"
}
},
{
"awardID": "067976-2025-2",
"dateSigned": "2025-10-21T00:00:00+01:00",
"id": "067976-2025-2",
"status": "active",
"title": "Lot 2 - NHS North-East and Yorkshire GMS",
"value": {
"amount": 5175000000.0,
"currency": "GBP"
}
},
{
"awardID": "067976-2025-3",
"dateSigned": "2025-10-21T00:00:00+01:00",
"id": "067976-2025-3",
"status": "active",
"title": "Lot 3 NHS Central and South GMS",
"value": {
"amount": 5175000000.0,
"currency": "GBP"
}
},
{
"awardID": "067976-2025-4",
"dateSigned": "2025-10-21T00:00:00+01:00",
"id": "067976-2025-4",
"status": "active",
"title": "Lot 4 NHS East GMS",
"value": {
"amount": 5175000000.0,
"currency": "GBP"
}
},
{
"awardID": "067976-2025-5",
"dateSigned": "2025-10-21T00:00:00+01:00",
"id": "067976-2025-5",
"status": "active",
"title": "Lot 5 NHS South-West GMS",
"value": {
"amount": 5175000000.0,
"currency": "GBP"
}
},
{
"awardID": "067976-2025-6",
"dateSigned": "2025-10-21T00:00:00+01:00",
"id": "067976-2025-6",
"status": "active",
"title": "Lot 6 NHS North Thames GMS",
"value": {
"amount": 5175000000.0,
"currency": "GBP"
}
},
{
"awardID": "067976-2025-7",
"dateSigned": "2025-10-21T00:00:00+01:00",
"id": "067976-2025-7",
"status": "active",
"title": "Lot 7 NHS South-East GMS",
"value": {
"amount": 5175000000.0,
"currency": "GBP"
}
}
],
"date": "2025-10-23T17:00:36+01:00",
"description": "This is a Provider Selection Regime (PSR) intention to award notice. This intention to award notice is subject to Regulation 10(7) of the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act Regulations 2023 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to the relevant authority by midnight on Tuesday 4th November 2025. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.\u003cbr/\u003eWritten representations should be sent to england.genomics@nhs.net, ensuring the following details are referenced:\u003cbr/\u003eProject reference: C368833\u003cbr/\u003eProject title: NHS Genomic Medicine Service - Most Suitable Provider process\u003cbr/\u003eThis decision has been made as per NHS England governance processes, by the Commercial Executive Group on 14th October 2025 and the National Commissioning Group on 21st October 2025. No conflicts of Interest were identified amongst decision-makers.\u003cbr/\u003eEach of the 5 key criteria were balanced with equal priority and considered on this basis and consideration was given to the basic selection criteria. Following provider assessments, it was agreed that the providers are the only providers capable of meeting the service specifications and requirements of the NHS GMS in full.\u003cbr/\u003e\u003cbr/\u003eAdditional CPV codes include:\u003cbr/\u003e85145000-7 (Services provided by medical laboratories),\u003cbr/\u003e85148000-8 (Medical analysis services)\u003cbr/\u003e85111810-1 (Blood analysis services)\u003cbr/\u003e85121200-5 (Medical specialist services)\u003cbr/\u003e85140000-2 (Miscellaneous health services)",
"id": "067976-2025",
"initiationType": "tender",
"language": "en",
"ocid": "ocds-h6vhtk-0565e9",
"parties": [
{
"address": {
"countryName": "United Kingdom",
"locality": "Leeds",
"postalCode": "LS1 4AP",
"region": "UKE",
"streetAddress": "7\u00268 Wellington Place"
},
"contactPoint": {
"email": "anna.salt@nhs.net",
"name": "Anna Salt"
},
"details": {
"buyerProfile": "https://www.england.nhs.uk//",
"classifications": [
{
"description": "Body governed by public law",
"id": "BODY_PUBLIC",
"scheme": "TED_CA_TYPE"
},
{
"description": "Health",
"id": "07",
"scheme": "COFOG"
}
],
"url": "https://www.england.nhs.uk//"
},
"id": "GB-FTS-118033",
"identifier": {
"legalName": "NHS England"
},
"name": "NHS England",
"roles": [
"buyer"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "Manchester",
"region": "UKD3"
},
"details": {
"scale": "large"
},
"id": "GB-FTS-18796",
"identifier": {
"legalName": "Manchester University NHS Foundation Trust"
},
"name": "Manchester University NHS Foundation Trust",
"roles": [
"supplier"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "Newcastle",
"region": "UKC2"
},
"details": {
"scale": "large"
},
"id": "GB-FTS-78899",
"identifier": {
"legalName": "The Newcastle upon Tyne Hospitals NHS Foundation Trust"
},
"name": "The Newcastle upon Tyne Hospitals NHS Foundation Trust",
"roles": [
"supplier"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "Birmingham",
"region": "UKG3"
},
"details": {
"scale": "large"
},
"id": "GB-FTS-1009",
"identifier": {
"legalName": "Birmingham Women\u2019s and Children\u2019s NHS Foundation Trust"
},
"name": "Birmingham Women\u2019s and Children\u2019s NHS Foundation Trust",
"roles": [
"supplier"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "Cambridge",
"region": "UKH1"
},
"details": {
"scale": "large"
},
"id": "GB-FTS-6625",
"identifier": {
"legalName": "Cambridge University Hospitals NHS Foundation Trust"
},
"name": "Cambridge University Hospitals NHS Foundation Trust",
"roles": [
"supplier"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "Bristol",
"region": "UKK1"
},
"details": {
"scale": "large"
},
"id": "GB-FTS-12898",
"identifier": {
"legalName": "North Bristol NHS Trust"
},
"name": "North Bristol NHS Trust",
"roles": [
"supplier"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "London",
"region": "UKI3"
},
"details": {
"scale": "large"
},
"id": "GB-FTS-95413",
"identifier": {
"legalName": "Great Ormond Street Hospital for Children NHS Foundation Trust"
},
"name": "Great Ormond Street Hospital for Children NHS Foundation Trust",
"roles": [
"supplier"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "London",
"region": "UKI3"
},
"details": {
"scale": "large"
},
"id": "GB-FTS-21063",
"identifier": {
"legalName": "Guy\u0027s and St Thomas\u0027 NHS Foundation Trust"
},
"name": "Guy\u0027s and St Thomas\u0027 NHS Foundation Trust",
"roles": [
"supplier"
]
},
{
"address": {
"countryName": "United Kingdom",
"locality": "Derby",
"postalCode": "DE1 3QT",
"streetAddress": "Cardinal Square, 10 Nottingham Road"
},
"details": {
"url": "https://www.ardengemcsu.nhs.uk/"
},
"id": "GB-FTS-141301",
"identifier": {
"legalName": "NHS Arden and Greater East Midlands Commissioning Support Unit"
},
"name": "NHS Arden and Greater East Midlands Commissioning Support Unit",
"roles": [
"reviewBody"
]
}
],
"tag": [
"award",
"contract"
],
"tender": {
"classification": {
"description": "Health services",
"id": "85100000",
"scheme": "CPV"
},
"description": "This is a notice of intention to make an award in respect of the NHS Genomic Medicine Service pursuant to the Most Suitable Provider (MSP) Process for the NHS Genomic Medicine Service (NHS GMS). For the avoidance of doubt, this is an intention to award notice. A notice of the confirmation of the award of each contract will be issued once they are signed.\u003cbr/\u003e\u003cbr/\u003ePursuant to the NHS GMS contracts, provider are to provide the following functions: \u003cbr/\u003e\u2022 Organisational leadership, governance and partnership arrangements;\u003cbr/\u003e\u2022 Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);\u003cbr/\u003e\u2022 Laboratory operating model;\u003cbr/\u003e\u2022 Clinical function: cancer genomics;\u003cbr/\u003e\u2022 Clinical function: rare disease;\u003cbr/\u003e\u2022 Clinical function: population health;\u003cbr/\u003e\u2022 Promotion of and supporting and leading where relevant science, research and / or innovation;\u003cbr/\u003e\u2022 Transformation and Service Improvement;\u003cbr/\u003e\u2022 People \u2013 workforce, education and training; and\u003cbr/\u003e\u2022 Data and digital",
"id": "C368833",
"items": [
{
"additionalClassifications": [
{
"description": "Health services",
"id": "85100000",
"scheme": "CPV"
}
],
"deliveryAddresses": [
{
"region": "UKD"
}
],
"id": "1",
"relatedLot": "1"
},
{
"additionalClassifications": [
{
"description": "Health services",
"id": "85100000",
"scheme": "CPV"
}
],
"deliveryAddresses": [
{
"region": "UKC"
}
],
"id": "2",
"relatedLot": "2"
},
{
"additionalClassifications": [
{
"description": "Health services",
"id": "85100000",
"scheme": "CPV"
}
],
"deliveryAddresses": [
{
"region": "UKG"
}
],
"id": "3",
"relatedLot": "3"
},
{
"additionalClassifications": [
{
"description": "Health services",
"id": "85100000",
"scheme": "CPV"
}
],
"deliveryAddresses": [
{
"region": "UKH"
}
],
"id": "4",
"relatedLot": "4"
},
{
"additionalClassifications": [
{
"description": "Health services",
"id": "85100000",
"scheme": "CPV"
}
],
"deliveryAddresses": [
{
"region": "UKK"
}
],
"id": "5",
"relatedLot": "5"
},
{
"additionalClassifications": [
{
"description": "Health services",
"id": "85100000",
"scheme": "CPV"
}
],
"deliveryAddresses": [
{
"region": "UKI"
}
],
"id": "6",
"relatedLot": "6"
},
{
"additionalClassifications": [
{
"description": "Health services",
"id": "85100000",
"scheme": "CPV"
}
],
"deliveryAddresses": [
{
"region": "UKJ"
}
],
"id": "7",
"relatedLot": "7"
}
],
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"lots": [
{
"awardCriteria": {
"criteria": [
{
"description": "100",
"name": "Most suitable provider process with regard to the key Criteria",
"type": "cost"
}
]
},
"description": "Pursuant to the NHS GMS contracts, providers are to provide the following functions:\u003cbr/\u003e*\tOrganisational leadership, governance and partnership arrangements;\u003cbr/\u003e*\tDelivery of genomic testing outlined in the National Genomic Test Directory (NGTD);\u003cbr/\u003e*\tLaboratory operating model;\u003cbr/\u003e*\tClinical function: cancer genomics;\u003cbr/\u003e*\tClinical function: rare disease;\u003cbr/\u003e*\tClinical function: population health;\u003cbr/\u003e*\tPromotion of and supporting and leading where relevant science, research and / or innovation;\u003cbr/\u003e*\tTransformation and Service Improvement;\u003cbr/\u003e*\tPeople \u2013 workforce, education and training; and\u003cbr/\u003e*\tData and digital\u003cbr/\u003eThe Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.\u003cbr/\u003eThe approximate lifetime value of the contract for all Lots is \u00a35,175,000,000.\u003cbr/\u003eThe services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).\u003cbr/\u003ePlease note that the figure included in the \u0027Awarded Value\u0027 section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).",
"hasOptions": true,
"id": "1",
"options": {
"description": "Options to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period."
},
"status": "cancelled",
"title": "Lot 1 \u2013 NHS North-West GMS"
},
{
"awardCriteria": {
"criteria": [
{
"description": "100",
"name": "Most suitable provider process with regard to the key Criteria",
"type": "cost"
}
]
},
"description": "Pursuant to the NHS GMS contracts, providers are to provide the following functions:\u003cbr/\u003e*\tOrganisational leadership, governance and partnership arrangements;\u003cbr/\u003e*\tDelivery of genomic testing outlined in the National Genomic Test Directory (NGTD);\u003cbr/\u003e*\tLaboratory operating model;\u003cbr/\u003e*\tClinical function: cancer genomics;\u003cbr/\u003e*\tClinical function: rare disease;\u003cbr/\u003e*\tClinical function: population health;\u003cbr/\u003e*\tPromotion of and supporting and leading where relevant science, research and / or innovation;\u003cbr/\u003e*\tTransformation and Service Improvement;\u003cbr/\u003e*\tPeople \u2013 workforce, education and training; and\u003cbr/\u003e*\tData and digital\u003cbr/\u003eThe Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.\u003cbr/\u003eThe approximate lifetime value of the contract for all Lots is \u00a35,175,000,000.\u003cbr/\u003eThe services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).\u003cbr/\u003ePlease note that the figure included in the \u0027Awarded Value\u0027 section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).",
"hasOptions": true,
"id": "2",
"options": {
"description": "Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period"
},
"status": "cancelled",
"title": "Lot 2 \u2013 NHS North-East and Yorkshire GMS"
},
{
"awardCriteria": {
"criteria": [
{
"description": "100",
"name": "Most suitable provider process with regard to the key Criteria",
"type": "cost"
}
]
},
"description": "Pursuant to the NHS GMS contracts, providers are to provide the following functions:\u003cbr/\u003e*\tOrganisational leadership, governance and partnership arrangements;\u003cbr/\u003e*\tDelivery of genomic testing outlined in the National Genomic Test Directory (NGTD);\u003cbr/\u003e*\tLaboratory operating model;\u003cbr/\u003e*\tClinical function: cancer genomics;\u003cbr/\u003e*\tClinical function: rare disease;\u003cbr/\u003e*\tClinical function: population health;\u003cbr/\u003e*\tPromotion of and supporting and leading where relevant science, research and / or innovation;\u003cbr/\u003e*\tTransformation and Service Improvement;\u003cbr/\u003e*\tPeople \u2013 workforce, education and training; and\u003cbr/\u003e*\tData and digital\u003cbr/\u003eThe Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.\u003cbr/\u003eThe approximate lifetime value of the contract for all Lots is \u00a35,175,000,000.\u003cbr/\u003eThe services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).\u003cbr/\u003ePlease note that the figure included in the \u0027Awarded Value\u0027 section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).",
"hasOptions": true,
"id": "3",
"options": {
"description": "Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period"
},
"status": "cancelled",
"title": "Lot 3 \u2013 NHS Central and South GMS"
},
{
"awardCriteria": {
"criteria": [
{
"description": "100",
"name": "Most suitable provider process with regard to the key Criteria",
"type": "cost"
}
]
},
"description": "Pursuant to the NHS GMS contracts, providers are to provide the following functions:\u003cbr/\u003e*\tOrganisational leadership, governance and partnership arrangements;\u003cbr/\u003e*\tDelivery of genomic testing outlined in the National Genomic Test Directory (NGTD);\u003cbr/\u003e*\tLaboratory operating model;\u003cbr/\u003e*\tClinical function: cancer genomics;\u003cbr/\u003e*\tClinical function: rare disease;\u003cbr/\u003e*\tClinical function: population health;\u003cbr/\u003e*\tPromotion of and supporting and leading where relevant science, research and / or innovation;\u003cbr/\u003e*\tTransformation and Service Improvement;\u003cbr/\u003e*\tPeople \u2013 workforce, education and training; and\u003cbr/\u003e*\tData and digital\u003cbr/\u003eThe Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.\u003cbr/\u003eThe approximate lifetime value of the contract for all Lots is \u00a35,175,000,000.\u003cbr/\u003eThe services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).\u003cbr/\u003ePlease note that the figure included in the \u0027Awarded Value\u0027 section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).",
"hasOptions": true,
"id": "4",
"options": {
"description": "Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period"
},
"status": "cancelled",
"title": "Lot 4 \u2013 NHS East GMS"
},
{
"awardCriteria": {
"criteria": [
{
"description": "100",
"name": "Most suitable provider process with regard to the key Criteria",
"type": "cost"
}
]
},
"description": "Pursuant to the NHS GMS contracts, providers are to provide the following functions:\u003cbr/\u003e*\tOrganisational leadership, governance and partnership arrangements;\u003cbr/\u003e*\tDelivery of genomic testing outlined in the National Genomic Test Directory (NGTD);\u003cbr/\u003e*\tLaboratory operating model;\u003cbr/\u003e*\tClinical function: cancer genomics;\u003cbr/\u003e*\tClinical function: rare disease;\u003cbr/\u003e*\tClinical function: population health;\u003cbr/\u003e*\tPromotion of and supporting and leading where relevant science, research and / or innovation;\u003cbr/\u003e*\tTransformation and Service Improvement;\u003cbr/\u003e*\tPeople \u2013 workforce, education and training; and\u003cbr/\u003e*\tData and digital\u003cbr/\u003eThe Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.\u003cbr/\u003eThe approximate lifetime value of the contract for all Lots is \u00a35,175,000,000.\u003cbr/\u003eThe services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).\u003cbr/\u003ePlease note that the figure included in the \u0027Awarded Value\u0027 section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).",
"hasOptions": true,
"id": "5",
"options": {
"description": "Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period"
},
"status": "cancelled",
"title": "Lot 5 \u2013 NHS South-West GMS"
},
{
"awardCriteria": {
"criteria": [
{
"description": "100",
"name": "Most suitable provider process with regard to the key Criteria",
"type": "cost"
}
]
},
"description": "Pursuant to the NHS GMS contracts, providers are to provide the following functions:\u003cbr/\u003e*\tOrganisational leadership, governance and partnership arrangements;\u003cbr/\u003e*\tDelivery of genomic testing outlined in the National Genomic Test Directory (NGTD);\u003cbr/\u003e*\tLaboratory operating model;\u003cbr/\u003e*\tClinical function: cancer genomics;\u003cbr/\u003e*\tClinical function: rare disease;\u003cbr/\u003e*\tClinical function: population health;\u003cbr/\u003e*\tPromotion of and supporting and leading where relevant science, research and / or innovation;\u003cbr/\u003e*\tTransformation and Service Improvement;\u003cbr/\u003e*\tPeople \u2013 workforce, education and training; and\u003cbr/\u003e*\tData and digital\u003cbr/\u003eThe Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.\u003cbr/\u003eThe approximate lifetime value of the contract for all Lots is \u00a35,175,000,000.\u003cbr/\u003eThe services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).\u003cbr/\u003ePlease note that the figure included in the \u0027Awarded Value\u0027 section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).",
"hasOptions": true,
"id": "6",
"options": {
"description": "Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period"
},
"status": "cancelled",
"title": "Lot 6 \u2013 NHS North Thames GMS"
},
{
"awardCriteria": {
"criteria": [
{
"description": "100",
"name": "Most suitable provider process with regard to the key Criteria",
"type": "cost"
}
]
},
"description": "Pursuant to the NHS GMS contracts, providers are to provide the following functions:\u003cbr/\u003e*\tOrganisational leadership, governance and partnership arrangements;\u003cbr/\u003e*\tDelivery of genomic testing outlined in the National Genomic Test Directory (NGTD);\u003cbr/\u003e*\tLaboratory operating model;\u003cbr/\u003e*\tClinical function: cancer genomics;\u003cbr/\u003e*\tClinical function: rare disease;\u003cbr/\u003e*\tClinical function: population health;\u003cbr/\u003e*\tPromotion of and supporting and leading where relevant science, research and / or innovation;\u003cbr/\u003e*\tTransformation and Service Improvement;\u003cbr/\u003e*\tPeople \u2013 workforce, education and training; and\u003cbr/\u003e*\tData and digital\u003cbr/\u003eThe Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.\u003cbr/\u003eThe approximate lifetime value of the contract for all Lots is \u00a35,175,000,000.\u003cbr/\u003eThe services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).\u003cbr/\u003ePlease note that the figure included in the \u0027Awarded Value\u0027 section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot. The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).",
"hasOptions": true,
"id": "7",
"options": {
"description": "Option to extend for up to a further 2 years (of 2 x 12 month periods) following the initial 8 year contract period"
},
"status": "cancelled",
"title": "Lot 7 \u2013 NHS South-East GMS"
}
],
"mainProcurementCategory": "services",
"procurementMethod": "limited",
"procurementMethodDetails": "Award procedure without prior publication of a call for competition",
"procurementMethodRationale": "This is a Provider Selection Regime (PSR) intention to award notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Procurement Act Regulations 2023 do not apply to this award. The standstill period begins on the day after the publication of this notice. Representations by providers must be made to decision makers by Tuesday 4th November 2025. This contract has not yet formally been awarded; this notice serves as an intention to award under the PSR.",
"procurementMethodRationaleClassifications": [
{
"description": "The procurement falls outside the scope of application of the directive",
"id": "D_OUTSIDE_SCOPE",
"scheme": "TED_PT_AWARD_CONTRACT_WITHOUT_CALL"
}
],
"status": "complete",
"title": "NHS Genomic Medicine Service - Most Suitable Provider Process"
}
}